Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Hepatology. 2014 Mar 3;59(4):1543–1554. doi: 10.1002/hep.26625

Figure 5. Protection against APAP-induced liver injury by Ro-31-8425 treatment is associated with enhanced p-AMPK levels and enhanced autophagy.

Figure 5

Figure 5

A) Effect of APAP and Ro-31-8425 pre-treatment on p-AMPK levels in vivo. B) Changes in autophagy markers (p62 degradation, LC3-II formation) following APAP treatment with or without Ro-31-8425 pre-treatment in vivo. * p value ≤ 0.05 versus APAP treatment at equivalent time points. ^ p value ≤ 0.05 versus control. # p value ≤ 0.05 versus respective controls (control or Ro-31-8425 without APAP treatment). N = 4–10 mice per group.